Congress-AHA
Congress-AHA-thumbnail

Transthyretin Amyloidosis (ATTR), Cardiovascular (CV)

American Heart Association (AHA) 2025

Congress Details

calanderNovember 7-10, 2025

locationNew Orleans, Louisiana

The material below is provided to support scientific exchange and pertains to select congress resources. Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.

All congress materials are copyrighted by Alnylam. Permission is required to copy or distribute.

For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.

Oral

Congress Materials

Filters

 

Therapeutic Areas

Transthyretin Amyloidosis (ATTR)

Razvi_AHA-2025_H-B-Cardiac-MRI-Poster-FINAL-Nov-7
icon Presentation Type
Poster
location icon Location
New Orleans, Louisiana
icon Title
Effects of Vutrisiran on Measures of Cardiac Structure, Function and Amyloid Burden by Cardiovascular Magnetic Resonance from the HELIOS-B Trial

Transthyretin Amyloidosis (ATTR)

Manafi_AHA25_H-B-RVFWS-poster_05Nov25_FINAL
icon Presentation Type
Poster
location icon Location
New Orleans, Louisiana
icon Title
Right Ventricular Free Wall Strain and Clinical Outcomes in Transthyretin Amyloid Cardiomyopathy and Effect of Vutrisiran: The HELIOS-B Study

Transthyretin Amyloidosis (ATTR)

Jering_AHA-LAS-HELIOS-B-20251104_FINAL_updated
icon Presentation Type
Poster
location icon Location
New Orleans, Louisiana
icon Title
Left Atrial Strain and Clinical Outcomes in Transthyretin Amyloidosis with Cardiomyopathy: Insights from the HELIOS-B Trial on Vutrisiran Efficacy

Transthyretin Amyloidosis (ATTR)

Sheikh_AHA-2025-H-B-Renal-Pos_D6.0_05Nov_FINAL
icon Presentation Type
Poster
location icon Location
New Orleans, Louisiana
icon Title
Vutrisiran Improved Outcomes Versus Placebo in Patients with Transthyretin Amyloidosis with Cardiomyopathy and Severe Chronic Kidney Disease: Post Hoc Analysis of HELIOS-B

Cardiovascular (CV)

AHA-2025-CV%29-KARDIA-3-A-randomized-trial-of-zilebesiran-versus-placebo-on-top-of-standard-care-for-patients-with-hypertension-and-established-cardiovascular-disease
icon Presentation Type
Presentation
location icon Location
New Orleans, Louisiana
icon Title
KARDIA-3: A randomized trial of zilebesiran versus placebo on top of standard care for patients with hypertension and established cardiovascular disease or high cardiovascular risk with or without chronic kidney disease

Related Materials

Transthyretin Amyloidosis (ATTR)

Effect of vutrisiran on components of health status in transthyretin amyloidosis with cardiomyopathy: the HELIOS-B study

European Journal of Heart Failure

Author(s)

Yasuhiro Hamatani, Brian L Claggett, Muthiah Vaduganathan, et al

March 2026

Transthyretin Amyloidosis (ATTR)

Efficacy and Safety of Vutrisiran in Patients with Hereditary Transthyretin-mediated Amyloidosis with Polyneuropathy: Analysis of the East Asian Subpopulation from HELIOS-A

Neurology and Therapy

Author(s)

Jeeyoung Oh, Yoshiki Sekijima, Hideki Mochizuki, et al

March 2026

Congress-AHA-thumbnail

Transthyretin Amyloidosis (ATTR), Cardiovascular (CV)

American College of Cardiology (ACC) 2026

March 28-30, 2026 USA

View Details
Congress-IPS-Mobile

Cardiovascular (CV)

Global Cardiovascular Clinical Trialists Forum (CVCT) 2025

December 8-10, 2025 USA

View Details
Congress-ISPOR-Mobile

Transthyretin Amyloidosis (ATTR)

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2025

November 9-12, 2025 UK

View Details

Transthyretin Amyloidosis (ATTR)

Efficacy and safety of vutrisiran in transthyretin amyloid cardiomyopathy across the age spectrum: The HELIOS-B trial

European Journal of Heart Failure

Author(s)

Awais Sheikh, Zi Michael Miao, Brian Claggett, et al

October 2025